Tag Archives: (NVO)

Blink And You Miss It

Did you know that the average person blinks about 17,000 times a day? Well, if you blinked during the American Diabetes Association conference, you might have missed Eli Lilly (LLY) delivering some of the most impressive clinical data I’ve seen in years. While their competitors stumbled through disappointing presentations, Lilly quietly demonstrated why they’re positioning […]

The Art Of War, Immunology Edition

Last month, as I pored over pharma earnings with a strong espresso and a stronger sense of deja vu, I was reminded why I swapped the lab coat for a Bloomberg terminal four decades ago. Markets may not speak Latin, but they sure know how to butcher nuance. And AbbVie (ABBV), dear readers, is a […]

How To Sell One Molecule Two Ways And Make Billions

Did you know Novo Nordisk’s (NVO) Ozempic and Wegovy are basically twins separated at birth? Both contain the same molecule — semaglutide — yet Wegovy costs three times more simply because it moonlights as a weight-loss drug instead of a diabetes treatment. That, my friends, is pharmaceutical sorcery so profitable it would make Merlin jealous. […]

Telehealth’s New Weight Class

Clinging to Mount Everest at 20,000 feet, fingers numb and oxygen tank hissing like an annoyed cobra, I had an epiphany that would later serve me well on Wall Street: the most promising paths aren’t always the obvious ones — they’re the routes that quietly keep you alive while everyone else is busy with their […]

The Weight Of Expectations

You know that feeling when you’ve found the perfect restaurant? The food is exquisite, the atmosphere divine, and then you get the bill—and suddenly you’re calculating if selling a kidney is a viable financial strategy. That’s essentially my relationship with Eli Lilly (LLY) right now. Phenomenal company, stellar performance, price tag that makes my wallet […]